Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
MediGene AG Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Martinsried/Munich May 21, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) announces that Dr. Axel Mescheder has been appointed the new Executive Board Member for Research & Development. Dr. Mescheder, previously head of Clinical Research & Development at MediGene, will take over the position of Executive Board Member from Dr. Ulrich Delvos, who will be resigning from the firm by mutual amicable agreement with the Company. Dr. Mescheder is a medical specialist in pharmacology and toxicology and has more than 15 years of management experience in clinical research & development at international pharmaceutical and biotech companies.
Dr. Peter Heinrich, Chairman of the Executive Board of MediGene AG, comments: "We are very pleased that Dr. Axel Mescheder will be assuming the important role of Executive Board Member for Research & Development. As head of clinical development for many years, he was responsible among other things for the successful development of our Veregen(TM) medication, which is available on the US market as the first proprietary development from a German biotech company. He also headed up the clinical development program of EndoTAG(TM)-1, which features impressive phase II data in the treatment of pancreatic cancer. I would like to express my sincere thanks to Dr. Ulrich Delvos for the valuable contributions he made during his four years on the Executive Board of MediGene and for the significant progress he achieved in MediGene's research & development department."
Axel Mescheder M. D. studied human medicine in Kiel and Cincinnati, USA, and received his license to practice medicine in 1986. Following his many years of medical and scientific work at the University Clinic of Kiel, the physician and medical specialist complete with doctor's degree started his industrial career as Medical and Product Manager at Hoffmann - La Roche AG, Grenzach/Germany in 1993. In 1997 he joined Aventis Behring, (Marburg, King of Prussia, USA), as the head of Intensive Care Europe before taking over the role of Director Clinical Research & Development at Genetic Institute GmbH, (Munich, Boston, USA), which was acquired by Wyeth International Pharma, in 1999. From 2001 to 2003, Dr. Mescheder served as Medical Director of MorphoSys AG, Martinsried/Germany. In February 2003 he joined MediGene AG as Vice President Clinical Research & Development.
Dr. Axel Mescheder, the new Executive Director of Research & Development at MediGene, comments: "I see a great deal of potential in MediGene's research and development projects and hold this company and its competent employees in extremely high esteem. I am therefore grateful that this challenging task has now been assigned to me and I very much look forward to further advancing the research & development of MediGene AG."
This press release contains forward-looking statements. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. The actual results achieved by MediGene may significantly differ from the statements made in these forward-looking statements. MediGene disclaims any obligation to update any of these forward-looking statements. MediGene(TM), EndoTAG(TM), and Veregen(TM) are trademarks of MediGene AG, Polyphenon® is a registered trademark of Mitsui Norin Co., Ltd., Oracea® is a registered trademark of CollaGenex Pharmaceuticals Inc., Eligard® is a registered trademark of QLT USA, Inc. These trademarks may be owned or licensed in select locations only.
- ends -
MediGene AG is a publicly quoted (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. Another drug candidate has just received official recommendation for marketing authorization by the EMEA. MediGene is planning to start its own marketing activities. The company has several drug candidates in clinical development, including two products which each have an annual sales potential of more than one billion Euros per year. MediGene also has projects in research and pre-clinical development and possesses innovative platform technologies for the development of active ingredients. MediGene concentrates on researching, developing and commercializing novel drugs in three therapeutic areas: cancer, autoimmune diseases, and skin diseases.
Contact MediGene AG E-mail: investor@medigene.com Fax:++49 - 89 - 85 65 - 2920 Julia Hofmann / Dr. Georg Dönges, Public Relations, Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim / Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
--- End of Message ---
MediGene AG Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090; ISIN: DE0005020903 ; Index: Prime All Share, CDAX, TECH All Share, HDAX, MIDCAP, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt in Frankfurter Wertpapierbörse;
